Williams, T, Wadeley, A, Bond, D, Cavill, C, Freeth, M and Sengupta, R (2020) 'Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.' Clinical Rheumatology, 39. pp. 1501-1504. ISSN 0770-3198
|
Text
13128.pdf - Accepted Version Repository Terms Apply. Download (1MB) | Preview |
Abstract
We reviewed our experience of treating ankylosing spondylitis patients with the IL-17 inhibitor secukinumab at the Royal National Hospital for Rheumatic Diseases, Bath. A total of 76 patients were included, of whom secukinumab was the first-line biologic drug used in 24, second line in 23, and third line in 29 patients, respectively. Only 5 patients discontinued the drug due to side effects before their first outpatient review, including 1 new case of inflammatory bowel disease. Significant improvements were seen in all disease outcome measures in patients receiving secukinumab as their first-line biologic agent, with a trend to improved mean BASDAI and BASFI even in patients receiving it as a second- or third-line biologic agent. This real-world analysis adds to the evidence recommending secukinumab as a largely safe and effective treatment for ankylosing spondylitis.
| Item Type: | Article |
|---|---|
| Note: | Categorised by the journal as a 'Brief Report'. |
| Keywords: | ankylosing spondylitis, biologic disease-modifying drug, secukinumab, KEF |
| Divisions: | School of Sciences |
| Identification Number: | https://doi.org/10.1007/s10067-020-04944-5 |
| Date Deposited: | 03 Mar 2020 14:15 |
| Last Modified: | 27 Feb 2024 14:34 |
| URI / Page ID: | https://researchspace.bathspa.ac.uk/id/eprint/13128 |
 |
Request a change to this item or report an issue |
 |
Update item (repository staff only) |
Tools
Tools
